Zenith Health Care Ltd
Incorporated in 1993, Zenith Health
care Ltd is engaged in manufacturing
and trading of pharma products[1]
- Market Cap ₹ 17.4 Cr.
- Current Price ₹ 3.24
- High / Low ₹ 4.99 / 2.23
- Stock P/E 1,741
- Book Value ₹ 1.38
- Dividend Yield 0.00 %
- ROCE 0.27 %
- ROE 0.13 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -5.20% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 1.22% over last 3 years.
- Working capital days have increased from 84.1 days to 122 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | 10.52 | |
| 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.23 | 11.24 | 10.65 | |
| Operating Profit | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.24 | 0.09 | -0.13 |
| OPM % | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.66% | 0.79% | -1.24% |
| 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.26 | 0.43 | 0.41 | |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 | 0.26 |
| Profit before tax | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 | 0.01 |
| Tax % | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% | 200.00% |
| -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | 0.01 | |
| EPS in Rs | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -53% |
| 3 Years: | -50% |
| TTM: | -83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -17% |
| 3 Years: | -5% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Reserves | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 | 2.05 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.56 | 3.48 | 3.57 | |
| Total Liabilities | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.99 |
| 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | 1.45 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.49 | 9.33 | 9.53 | |
| Total Assets | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.99 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.67 | -0.83 | |
| -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -1.88 | -1.09 | 0.85 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | |
| Net Cash Flow | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | -0.14 | -0.41 | 0.01 |
| Free Cash Flow | -0.18 | 0.11 | 0.11 | 0.00 | -0.11 | 1.45 | -1.66 | 1.08 | -0.95 | 1.63 | 0.28 | -0.99 |
| CFO/OP | -475% | -100% | 383% | 0% | -15% | 356% | -372% | 333% | -2,967% | 796% | 800% | 615% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 57.26 | 77.96 | 72.51 |
| Inventory Days | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 86.65 | 152.87 | 219.75 |
| Days Payable | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 38.08 | 91.59 | 112.89 |
| Cash Conversion Cycle | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 105.84 | 139.24 | 179.38 |
| Working Capital Days | 246.68 | 208.87 | 136.40 | 82.13 | 96.17 | 48.14 | 98.02 | 50.93 | 116.76 | 60.54 | 69.59 | 122.13 |
| ROCE % | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.12% | 0.27% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Export Revenue Share (% of total revenue) % |
|
|||||||||
| Manufactured Goods Share of Direct Cost % |
||||||||||
| Number of Countries with Plant Registrations count |
||||||||||
| Capital Expenditure (Purchase of fixed assets) INR Lakhs |
||||||||||
| Number of Permanent Employees count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Board Meeting Held On Tuesday, July 14, 2026 And The Disclosure Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding The Approval Of The Scheme Of Amalgamation Of Achyut Healthcare Limited With And Into Zenith Healthcare Limited.
14 Jul - Board approved amalgamation of Achyut Healthcare into Zenith Healthcare, subject to NCLT and shareholder approvals.
-
Corporate Action-Amalgamation/ Merger / Demerger
14 Jul - Board approved July 14, 2026 amalgamation of Achyut Healthcare into Zenith; 119 shares for 50, subject to NCLT.
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
14 Jul - Board approved amalgamation of Achyut Healthcare into Zenith, subject to NCLT/shareholder approvals; 119 shares for 50.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - Submitted RTA certificate under Regulation 74(5) for quarter ended 30 June 2026.
- Closure of Trading Window 26 Jun
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
ZHL is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms.
The services include purchasing of raw materials, production, packaging, and quality control, and offering solid dosage forms in General and Beta-Lactam Tablets, Capsules, Oral Liquids, and Dry Powder Oral Suspension.